Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-279-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$694.02 million
Profitability
Miscellaneous
Employees2,191
Next Earnings DateN/A
OptionableOptionable
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) posted its earnings results on Tuesday, May, 7th. The company reported ($0.10) EPS for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.08. The firm had revenue of $165.90 million for the quarter, compared to the consensus estimate of $153.01 million. Akorn had a negative net margin of 67.38% and a negative return on equity of 13.92%. The firm's revenue for the quarter was down 9.9% compared to the same quarter last year. View Akorn's Earnings History.
What guidance has Akorn issued on next quarter's earnings?
Akorn updated its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $690-710 million, compared to the consensus revenue estimate of $633.47 million.
What price target have analysts set for AKRX?
6 brokerages have issued 1 year price objectives for Akorn's stock. Their predictions range from $4.00 to $11.00. On average, they expect Akorn's stock price to reach $6.80 in the next twelve months. This suggests a possible upside of 62.3% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.
Has Akorn been receiving favorable news coverage?
Media headlines about AKRX stock have been trending negative this week, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akorn earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR), Nabriva Therapeutics (NBRV), Arrowhead Pharmaceuticals (ARWR), Allakos (ALLK), Pacira Biosciences (PCRX), Tricida (TCDA), Enanta Pharmaceuticals (ENTA), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Zogenix (ZGNX) and Zai Lab (ZLAB).
What other stocks do shareholders of Akorn own?
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
- Dr. Bruce Kutinsky, Consultant (Age 53)
- Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.25%), Renaissance Technologies LLC (5.62%), AQR Capital Management LLC (2.61%), Dimensional Fund Advisors LP (2.58%), Goldman Sachs Group Inc. (1.12%) and Northern Trust Corp (1.04%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky, John N Kapoor, Joseph Bonaccorsi and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.
Which major investors are selling Akorn stock?
AKRX stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, J. Goldman & Co LP, Assenagon Asset Management S.A., Morgan Stanley, JPMorgan Chase & Co., Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc. and State of Wisconsin Investment Board. View Insider Buying and Selling for Akorn.
Which major investors are buying Akorn stock?
AKRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, AQR Capital Management LLC, Dimensional Fund Advisors LP, Jacobs Levy Equity Management Inc., Macquarie Group Ltd., Connor Clark & Lunn Investment Management Ltd., Sivik Global Healthcare LLC and Spark Investment Management LLC. Company insiders that have bought Akorn stock in the last two years include Joseph Bonaccorsi and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $4.19.
How big of a company is Akorn?
Akorn has a market capitalization of $527.31 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
